Back to Newsroom

Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ(R) (lorcaserin HCl) CIV by 50%

— Expansion to Approximately 600 Sales Specialists Follows Initiation of National Television Advertising Campaign —
— Access to Reimbursement Coverage Now Exceeds 60% —

SAN DIEGO, May 9, 2014 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai plans to add more than 200 new contract sales representatives to its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600, triple the size from the commercial launch of BELVIQ in June 2013. Eisai expects this expansion of the sales force will become effective on July 1, 2014, and enable them to reach approximately 90,000 physicians in the United States.

Click here to read more